The Inflation Reduction Act (IRA) takes important steps to reduce drug prices and lower costs for people with Medicare and the program, such as capping beneficiary out-of-pocket spending; requiring Medicare to negotiate drug prices; and expanding eligibility for the full Part D low-income subsidy (LIS). We support an implementation process that centers the beneficiary experience and look forward to building upon these landmark policies.
The Inflation Reduction Act (IRA) made significant improvements to Medicare prescription drug access and affordability, including by restructuring the Part
Key components of the Inflation Reduction Act’s Part D reforms will be fully implemented for plans offered in 2025. These
Medicare open enrollment is just around the corner, and there will be major changes in 2025 that beneficiaries should keep in mind, and some of these changes may affect what plans people choose.
On Monday, Medicare Rights Center President Fred Riccardi participated in a press conference with Senator Kirsten Gillibrand. He spoke about the importance of key Inflation Reduction Act (IRA) cost protections for people with Medicare, in particular the law’s safeguards against unlimited enrollee expenses for covered Part D drugs.
Today, Medicare Rights Center President Fred Riccardi spoke in support of the Capping Prescription Costs Act (S. 4671/H.R. 6347), legislation to extend key Inflation Reduction Act reforms to people with group health and marketplace plans.
–Statement by Fred Riccardi, president of the Medicare Rights Center– New York, NY—As we celebrate two years since the passage
In a historic first, the Biden-Harris administration today announced the results of the initial round of drug price negotiation made
It has been two years since the passage of the Inflation Reduction Act of 2022 (IRA). The landmark legislation included
In 2023, the Centers for Medicare & Medicaid Services (CMS) opened a review to determine if Medicare should cover Preexposure
This week, the Centers for Medicare & Medicaid Services (CMS) announced a new project designed to help keep costs and
The Inflation Reduction Act (IRA) made significant improvements to Medicare prescription drug access and affordability, including by restructuring the Part
Key components of the Inflation Reduction Act’s Part D reforms will be fully implemented for plans offered in 2025. These
Medicare open enrollment is just around the corner, and there will be major changes in 2025 that beneficiaries should keep in mind, and some of these changes may affect what plans people choose.
On Monday, Medicare Rights Center President Fred Riccardi participated in a press conference with Senator Kirsten Gillibrand. He spoke about the importance of key Inflation Reduction Act (IRA) cost protections for people with Medicare, in particular the law’s safeguards against unlimited enrollee expenses for covered Part D drugs.
Today, Medicare Rights Center President Fred Riccardi spoke in support of the Capping Prescription Costs Act (S. 4671/H.R. 6347), legislation to extend key Inflation Reduction Act reforms to people with group health and marketplace plans.
–Statement by Fred Riccardi, president of the Medicare Rights Center– New York, NY—As we celebrate two years since the passage
In a historic first, the Biden-Harris administration today announced the results of the initial round of drug price negotiation made
It has been two years since the passage of the Inflation Reduction Act of 2022 (IRA). The landmark legislation included
In 2023, the Centers for Medicare & Medicaid Services (CMS) opened a review to determine if Medicare should cover Preexposure
This week, the Centers for Medicare & Medicaid Services (CMS) announced a new project designed to help keep costs and
